Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient
A

ASH 2019 AML Update: Maintenance Therapy is Likely to Become Standard - Update on Trials with Oral Azacitidine & Gilteritinib

By Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient FEATURING Alexander Perl
By Penn Medicine's 2020 Updates in Care of the Hematologic Malignancies Patient FEATURING Alexander Perl
415 views
February 24, 2020
1 Comment
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Related Content

AUTOPLAY
22:37
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…

Feat. T. Badar
50:34
Scripps MD Anderson Cancer Center

The Cure of Leukemias in the Next Decade: An Optimist’s View

Feat. H. Kantarjian
19:10
5th SOHO Italy Annual Conference

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

Feat. H. Kantarjian
09:51
i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje
14:19
Talha Badar

Challenges in the Management of TP53-Mutated AML: Potential Strategi…

22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
14:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai
27:28
UChicago Medicine

AML: Current Treatment Landscape and Key Recent Updates

Feat. A. Patel
12:28
Roswell Park Comprehensive Cancer Center

Current Landscape of R/R AML Treatment

Feat. E. Wang
02:52
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Results From a Phase 1 Clinical Study of …

Feat. M. Amaya
32:04
Moffitt Cancer Center

Experts Discuss the Latest Data in Myeloid Diseases

Feat. A. Kuykendall, R. Komrokji, O. Chan, D. Sallman
40:21
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Overview of Hematopoietic Cell Transplantation

Feat. R. Salit
15:45
SOHO 2022 Tenth Annual Meeting

SOHO 2022: How Do We Overcome Resistance to Venetoclax in AML

Feat. M. Konopleva
16:11
MyCancerHaven

Experts Discuss the Use of Targeted Therapies in AML

Feat. R. Vij, E. Wang
04:11
Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman
19:51
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A 50-Year Personal Perspective on the Treatment of AML

Feat. C. Schiffer
11:41
Penn Medicine Abramson Cancer Center

Penn Medicine Updates From Recent Meetings in Hematologic Malignanci…

Feat. C. Lai
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
10:41
ASH 2022 Conference Coverage

ASH 2022 Triplet Combination of Azacitidine, Venetoclax, and Gilteri…

Feat. N. Short
35:15
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: AML

Feat. F. Ravandi